anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Evaluate women for ectopic pregnancy if they become pregnant with Kyleena in place because the likelihood of a pregnancy being ectopic is increased with Kyleena. Approximately one-half of pregnancies that occur with Kyleena in place are likely to be ectopic. Also consider the possibility of ectopic pregnancy in the case of lower abdominal pain, especially in association with missed menses or if an amenorrheic woman starts bleeding. 

The incidence of ectopic pregnancy in clinical trials with Kyleena, which excluded women with a history of ectopic pregnancy, was approximately 0.2% per year. The risk of ectopic pregnancy in women who have a history of ectopic pregnancy and use Kyleena is unknown. Women with a previous history of ectopic pregnancy, tubal surgery or pelvic infection carry a higher risk of ectopic pregnancy. Ectopic pregnancy may result in loss of fertility.
The invention discloses LncRNA for regulating apoptosis and proliferation of placenta trophoblasts in an ICP process and application thereof. Use of a substance that inhibits LncRNARP's expression of 11-782C8.5 in the manufacture of a medicament for the treatment of intrahepatic cholestasis during gestation. The present invention found that LncRNARP-782C8.5 was highly expressed in placenta of patients with intrahepatic cholestasis of pregnancy (FIG. 1), and in placenta trophoblasts of ICP model (FIG. 2). After successful low expression of LncRNARP-782C8.5 in HTR8/SVneo cells by design of siRNA, apoptosis was inhibited (fig. 3) and cell proliferation was promoted (fig. 4). Therefore, the siRNA of LncRNARP-782C8.5 or the substance or the vector for inhibiting the expression thereof can be applied to the preparation of the medicine for relieving ICP.
Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action. In addition they will be able to download the MMM app, which will store text messages received. Additionally, participants in this arm will be able to link within the app to a private Facebook page. Participants can access this page through their app or directly via Facebook where they can view, comment, and share in response to posts. The MMM app has three main elements: text messages via push notification are stored and searchable on the app, access to a breastfeeding social support group on Facebook, and access to videos and written material to facilitate knowledge acquisition and skills building.
The most frequent adverse events reported with the use of ketorolac tromethamine ophthalmic solutions have been transient stinging and burning on instillation. These events were reported by up to 40% of patients participating in clinical trials.

Other adverse events occurring approximately 1 to 10% of the time during treatment with ketorolac tromethamine ophthalmic solutions included allergic reactions, corneal edema, iritis, ocular inflammation, ocular irritation, superficial keratitis, and superficial ocular infections.

Other adverse events reported rarely with the use of ketorolac tromethamine ophthalmic solutions included: corneal infiltrates, corneal ulcer, eye dryness, headaches, and visual disturbance (blurry vision).

Clinical Practice: The following events have been identified during postmarketing use of ketorolac tromethamine ophthalmic solution 0.5% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical ketorolac tromethamine ophthalmic solution 0.5% or a combination of these factors, include corneal erosion, corneal perforation, corneal thinning, and epithelial breakdown (see PRECAUTIONS, General).
The invention relates to a kind of animal agentia and the preparative of it, which has something to do with the animal drug technology. The material of the agentia is plantaginis, which can relieve the fever, induce urination, intoxicate and eliminate phlegm. The making procedures go as follows: remove the impurities of plantaginis and clean it thoroughly; cut it into several sections and crush the plantaginis; extract the smashed plantaginis; mix the filtered solutions together; dry the solution into powder and smash it into refined plantaginis powder. The extracting procedure includes two steps mainly, the first step is extracting the material in solution at ph2-5(adjusted by 10% acid solution) for 2 hours; the second step is extracting the material in solution at ph8-9(adjusted by 10% acid solution) for 8-9 hours. The agentia can treat the loimia of livestocks and poultries very effectively. The processing technology adopts the water-extracting method, besides it adopts acids before alkaline during extracting so that it can retain the effective ingredient of the drug. The effective ingredients of the refined powder have overcome the absorption problem of plantaginis, so that the agentia can increase the economic benefits and decrease the producing cost of the animal agentia.
The matching placebo will be also custom-produced and will be produced in the same manner, without the active ingredients by the same company. The placebo produced will match with vitamin D3 in terms of appearance, size, colour and taste to achieve the double-blind design.
Neonatal ileal atresia is a form of intestinal obstruction characterized by narrowing, complete closure, or absence of a segment of the ileum. This case involves a 5-day-old female neonate presented with abdominal distension and bilious vomiting. The neonate, delivered via spontaneous vertex birth weighing 2.9 kg, showed no fever and maintained stable vital signs during examination. Physical assessment revealed abdominal distension, hyper-tympanic areas, dullness in the lower quadrants, reduced bowel sounds, and a patent anus with an empty rectum. Imaging studies confirmed intestinal obstruction from dilated small bowels, leading to explorative laparotomy identifying ileal atresia, necessitating cecostomy placement. Despite surgical intervention, the neonate experienced nutritional complications and unfortunately passed away three days postoperatively. This case underscores the complexities of early diagnosis and management in neonates with intrauterine conditions, particularly in resource-limited settings with limited access to total parenteral nutrition.
Procedure for the preparation of the imidazole derivative of formula (I). Consisting in reacting the compound (II) with dimethylamine in a pressure reactor, verifying the reaction at a pressure comprised between 2 and 10 atmospheres and at temperature comprised between 20 and 80gc. Methanol, ethanol, ethyl acetate or tetrahydrofuran is used as a solvent, maintaining a nitrogen atmosphere in the reactor. The product is precipitating as it is formed, and at the end of the reaction it is collected by filtration. The product obtained has citostatic properties, used mainly in the treatment of sarcoma and metastatic melanoma. * formula * r (Machine-translation by Google Translate, not legally binding)
The invention discloses a traditional Chinese medicine composition for treating chicken infectious bronchitis and a preparation method thereof, and belongs to the technical field of veterinary traditional Chinese medicine. The traditional Chinese medicine composition is mainly composed of the following traditional Chinese herbals in parts by weight: 200 to 300 parts of ephedra stem, 150 to 300 parts of folium isatidis, 100 to 250 parts of gypsum, 100 to 200 parts of fructus forsythiae, 100 to 200 parts of coptis, 100 to 200 parts of honeysuckle flower, 50 to 150 parts of dandelion, 70 to 150 parts of radix scutellariae, 120 to 150 parts of almond, 100 to 120 parts of dwarf lilyturf tuber, 50 to 150 parts of mulberry bark, 100 to 150 parts of radix scrophulariae, 70 to 100 parts of garden burnet, 10 to 50 parts of licorice, 100 to 150 parts of balloonflower root, and 50 to 150 parts of chrysanthemum. The traditional Chinese herbals mentioned above are compounded according to the principle of "monarch, minister, assistant and guide" in traditional Chinese medicine. The traditional Chinese herbals are co-used to generate the functions of preventing bacteria, inflammation, and viruses, invigorating the stomach, nourishing the spleen, and modulating and strengthening the organism immunity. The traditional Chinese medicine composition is mainly used to prevent and treat chicken infectious bronchitis, and has the advantages of rapid and definite effect. Moreover, the traditional Chinese medicine composition is completely composed of pure traditional Chinese herbals, and has the advantages of low price, safety, no drug residue, and no side or toxic effect on poultry.
In the United States alone, 10 million people are affected by family and domestic violence (DV). DV survivors experience many forms of victimization, including physical, psychological, and sexual abuse resulting in trauma. The DV workforce, including healthcare providers, social workers, advocates, and other providers, utilize trauma-informed care in a variety of settings to help DV survivors heal and recover from their traumatic experiences. Given the intensity of DV work and occupational stressors associated with navigating complex survivor cases and systems of care, health and mental health professionals can experience burnout, compassion fatigue, and secondary traumatic stress. The purpose of this qualitative study was to explore how professionals in the DV workforce, including healthcare and mental health professionals, experience and mitigate occupational stress. Twenty in-depth interviews were conducted with DV professionals, who worked in medical settings like urban hospitals as well as DV shelters and rape crisis centers in Boston, MA. A semistructured interview guide was developed, and pilot tested and addressed the following topics including experiences of occupational stress, and mitigators of occupational stress. The interviews were audio recorded, transcribed, and analyzed using a thematic analysis approach. Codes were organized into themes and subthemes, which were reviewed and refined during research team discussions. Risk factors of occupational stress included caseload quantity and intensity, workplace isolation, and length of time in the field. Protective factors spanned individual, interpersonal, and organizational level factors. Participants described various strategies for mitigating occupational stress, including training, supervision, and self-care. Findings from this study have the potential to inform policies and practices among healthcare organizations that support professionals in the DV workforce who work with DV survivors.
A system, method and apparatus provide a self-registration service to potential victims located in proximity to an incident event. An incident-specific URL is pushed to communication devices located in proximity to the incident. The incident-specific URL links to a self-registration website that enables victims to upload their health related information. The incident-specific URL and self-registration website enables identifying potential victims along with their health status for tracking during a mass casualty incident (MCI). The service may further include providing self-triage information and the tracking of “self-help” victims, with minor injuries. The service can further exchange information with health service providers (HSPs) to facilitate patient tracking and status updates.
Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Day 0 and Month 6. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL Intramuscular (IM), concomitantly with the first 2 doses of CYD dengue vaccine.
PURPOSE:To produce a clathrate compd. having a form supporting structure, thixotropic property and gradually releasing property and high in essential oil content by using the essential oil as a guest and a lipophilic swellable laminar silicate as a host body. CONSTITUTION:This clathrate compd. is produced from essential oil as the guest and the lipophilic swellable laminar silicate as the host body. For example, 1-99wt.%, preferably 10-30wt.% lipophilic swellable laminar silicate is added to 1-99wt.% preferably 70-90wt.% essential oil, and agitated. This clathrate compd. is used alone or by being mixed with other substance and used as a material for a cream, ointment, cosmetics, coating material and perfume.
FIELD: medicine, vaccines. SUBSTANCE: invention relates to vaccine composition involving antigen, 3-de-O-acylated monophosphoryllipid-A and QS-21 as an adjuvant. This composition shows property to cause cytolytic T-cellular response in mammals. Invention relates to a method of preparing this vaccine by mixing antigen with 3-de-O-acylated monophosphoryllipid-A in an aqueous suspension followed by addition of QS-21 in an aqueous solution with sodium chloride at pH 6.5 ± 0.5. Vaccine composition shows property to induce the broadened pattern of immune responses as compared with the known ones. EFFECT: enhanced effectiveness of vaccine composition. 8 cl, 3 ex, 2 tbl
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis. Ketorolac tromethamine given systemically does not cause pupil constriction. 

Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure. Prostaglandins also appear to play a role in the miotic response produced during ocular surgery by constricting the iris sphincter independently of cholinergic mechanisms. 

Two drops (0.1 mL) of 0.5% ACULAR® ophthalmic solution instilled into the eyes of patients 12 hours and 1 hour prior to cataract extraction achieved measurable levels in 8 of 9 patients' eyes (mean ketorolac concentration 95 ng/mL aqueous humor, range 40 to 170 ng/mL). Ocular administration of ketorolac tromethamine reduces prostaglandin E2 (PGE2) levels in aqueous humor. The mean concentration of PGE2 was 80 pg/mL in the aqueous humor of eyes receiving vehicle and 28 pg/mL in the eyes receiving ACULAR® 0.5% ophthalmic solution. 

One drop (0.05 mL) of 0.5% ACULAR® ophthalmic solution was instilled into one eye and one drop of vehicle into the other eye TID in 26 normal subjects. Only 5 of 26 subjects had a detectable amount of ketorolac in their plasma (range 10.7 to 22.5 ng/mL) at Day 10 during topical ocular treatment. When ketorolac tromethamine 10 mg is administered systemically every 6 hours, peak plasma levels at steady state are around 960 ng/mL. 

Two controlled clinical studies showed that ACULAR® ophthalmic solution was significantly more effective than its vehicle in relieving ocular itching caused by seasonal allergic conjunctivitis. 

Two controlled clinical studies showed that patients treated for two weeks with ACULAR® ophthalmic solution were less likely to have measurable signs of inflammation (cell and flare) than patients treated with its vehicle. 

Results from clinical studies indicate that ketorolac tromethamine has no significant effect upon intraocular pressure; however, changes in intraocular pressure may occur following cataract surgery.
The research was carried out with children and adolescents aged 8-18 years who were followed up with the diagnosis of Type 1 Diabetes Mellitus in Gaziantep Cengiz Gökçek Gynecology and Pediatrics Hospital. The sample of the study was consisted of 75 (male= 36, female= 39) children and adolescents in total, including Intervention 1 group (n=25), Intervention 2 (n=25) group and Control (n=25) group determined by double-blind, stratified, random method. Medical nutrition therapy and carbohydrate counting training were given to mothers and children in the Intervention 1 group, and only to children and adolescents in the Intervention 2 group. The control group did not receive medical nutrition therapy and carbohydrate counting training. At the beginning (0. month) and at the end (6. month) of the study, 3 consecutive day/24-hour food consumption records and anthropometric measurements of the individuals were assessed, BMI z-scores and height z-scores were calculated, Mediterranean Diet Quality Index Scale (KIDMED), Diabetes Eating Problems Survey-Revised (DEPS-R), Physical Activity Questionnaire for Children and Adolescents (PAQ-C and PAQ-A) were administered and Healthy Eating Index 2015 (HEI-2015) scores were calculated. Routinely assessed blood findings of the individuals were checked at the beginning (0. month), 3rd month and 6th month of the study.
PROBLEM TO BE SOLVED: To obtain scaly powder having high protecting ability against not only UVB but also UVA and to obtain an external preparation for skin capable of effectively preventing photoaging and damage of skin resulting especially from UVA. SOLUTION: Scaly powder is coated with titanium oxide containing tungsten or molybdenum in the interior of crystal. One or more are selected from these coated scaly powders are added to an external preparation for skin. The coating treatment of the scaly powder can be carried out by a deposition method or physical and chemical mixed grinding method. The content of tungsten or molybdenum in the titanium oxide is 0.1-20 wt.%. The application amount of the titanium oxide containing tungsten or molybdenum is preferably about 1.0-60.0 wt.%.
Randomized: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
Atrial fibrillation (AF), a supraventricular tachyarrhythmia, is the primary diagnosis for over 467,000 hospitalizations each year. Historically, there have been two approaches to managing AF in the emergency department (ED): rate control and rhythm control.

The AFFIRM trial compared rate and rhythm control in 4,060 patients. It found no difference in mortality with the rate control approach and less hospitalizations. As a result, both rhythm and rate control are options in stable patients with an AF duration of \< 48 hours. After 48 hours, rate control is preferred because of the increased risk of ischemic stroke. The subsequent RACE II trial, established that lenient heart rate control (HR \<110 beats/min) was as effective as strict control (HR \<80 beats/min) in preventing cardiovascular events and required less outpatient visits to achieve the goal HR. As a result of both the AFFIRM and RACE II trials, a rate control approach with a goal HR of \<80-110 beats/min is the management plan for a majority of patients who present to the ED in AF. According to the American Heart Association 2014 guidelines, the initial acute, emergent management of atrial fibrillation and flutter (AFF) are similar and there are a number of medications used for rate control including beta blockers and non-dihydropyridine calcium channel blockers.

Diltiazem, a non-dihydropyridine calcium channel blocker, is often the medication of choice in the management of AFF due to its ability to be given as an intravenous (IV) push, continuous infusion, and oral (PO) immediate release or extended release tablet. In the ED, a loading dose of IV diltiazem 0.25 mg/kg is usually administered to obtain a heart rate of \< 110 beats/min or a decrease of at least 20% in the ventricular rate. If this does not work then a second bolus of 0.35mg/kg is administered. Once rate control of \<110 beats/min or a 20% decrease in ventricular rate is obtained physicians typically chose between oral immediate release diltiazem tablet or IV continuous infusion diltiazem to maintain heart rate control. Both options allow for dose changes in the short term. The oral immediate release diltiazem tablet has a fast onset of action of 30-60 minutes and is dosed every 6 hours. Intravenous continuous infusion diltiazem has a variable onset of action with a titration frequency of every 15-30 minutes. The use of oral diltiazem allows for possible placement on a monitored general floor bed, whereas an intravenous drip requires placement to step down or intensive level of care. This impacts bed status and length of stay in the emergency department. Both oral and intravenous diltiazem are used clinically; however, no prospective studies exist comparing the two strategies. Retrospective data suggests that both forms are equal in their ability to control heart rate.
This is a 2-part study to be conducted at a single study center. Part 1 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of CC-90001 following a single oral dose in healthy subjects. During the course of Part 1, each subject will participate in a screening phase, a baseline phase, a treatment phase and a follow up visit. There will be a total of 7 planned cohorts, each of which will consist of a different dose level, with 8 subjects per cohort. In each cohort, 6 subjects will receive a dose of CC 90001 and 2 subjects will receive placebo depending on the randomization schedule. Administration of study drug at the next higher dose level will not begin until the safety and tolerability of the preceding dose have been evaluated and deemed acceptable by the investigator and sponsor's medical monitor. Part 2 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of CC-90001 following multiple oral doses in healthy subjects. Only doses that are safe and well tolerated in Part 1 will be administered in Part 2. During the course of Part 2, each subject will participate in a screening phase, a baseline phase, a treatment phase and a follow up visit. There will be a total of up to 6 planned cohorts, each of which will consist of a different dose level, with 8 subjects per cohort. In each cohort, 6 subjects will receive a dose of CC 90001 and 2 subjects will receive placebo depending on the randomization schedule. It is planned for study drug to be administered once daily for up to 14 days. Proposed dose levels in Part 2 may be modified and/or eliminated based on data obtained from Part 1; however, the maximum dose administered in Part 2 will not exceed the maximum tolerated dose in Part 1.